1. A Comprehensive Analysis of Neoadjuvant Chemotherapy in Breast Cancer: Adverse Events, Clinical Response Rates, and Surgical and Pathological Outcomes—Bozyaka Experience.
- Author
-
Yılmaz, Cengiz, Zengel, Baha, Üreyen, Orhan, Adıbelli, Zehra Hilal, Taşlı, Funda, Yılmaz, Hasan Taylan, Özdemir, Özlem, Kocatepe Çavdar, Demet, Mollamehmetoğlu, Hülya, Çakıroğlu, Umut, İmren, Yaşar, Yakan, Savaş, and İlhan, Enver
- Subjects
SENTINEL lymph node biopsy ,BREAST tumors ,PATHOLOGIC complete response ,AXILLARY lymph node dissection ,DRUG therapy ,RETROSPECTIVE studies ,CANCER chemotherapy ,COMBINED modality therapy ,MEDICAL records ,ACQUISITION of data ,ANTHRACYCLINES ,CARDIOTOXICITY ,MASTECTOMY ,DISEASE progression ,LUMPECTOMY - Abstract
Simple Summary: This study aimed to evaluate and analyze the neoadjuvant chemotherapy (NACTx) processes and surgical and pathological outcomes in breast cancer (BC). NACTx for BC caused grade ≥ 3 adverse events in one-fifth of the patients in our study. Anthracyline cardiotoxicity (2.2%) resulted in one death (0.4%). Clinical disease progression occurred in 3.9% of the cases (14% in triple-negative BC). Cavity shaving was required in one-fifth of the patients. We found that invasive lobular carcinoma (ILC) and tumors with low SUVmax values are very risky for positive surgical margins. Axillary clinical complete response is not reliable for luminal A (LA) BC and ILC, but trustworthy for HER2-enriched and triple-negative BC. It was also found that the need for ALND decreases with HER2(+) disease and higher SUVMax values of axillary lymph nodes, but increases with ER positivity and higher PR expression levels. A pathologic complete response is unlikely in well-defined LA BC. Objectives: To evaluate the neoadjuvant chemotherapy (NACTx) process in breast cancer (BC), its significant treatment-related adverse events (trAEs), tumor clinical response rates, and surgical and pathological outcomes, and to analyze factors influencing cavity shaving and axillary lymph node dissection (ALND) following sentinel lymph node biopsy (SLNB). Methods: A comprehensive retrospective study was conducted at a single center on patients who received NACTx for BC between 2015 and 2021. Results: Medical records of 242 patients were reviewed. Approximately one-fifth encountered grade ≥ 3 trAEs (21.5%), leading 3.3% to discontinue chemotherapy. Anthracycline cardiotoxicity (2.2%) caused one death (mortality rate = 0.4%). For clinical response and surgical and pathological outcomes, 229 patients were eligible. Clinical progression occurred in 3.9% of the patients (14% in triple-negative BC, p = 0.004). Breast-conserving surgery (BCS) was performed in 55% of the patients. There was no significant difference between the type of breast surgery (BCS vs. mastectomy) and molecular subtype, histology, tumor size, or tumor's pathological response degree. Cavity shaving was required in one-fifth of the patients who underwent BCS (n = 134) due to an invasive tumor at the surgical margin (SM). Tumor histology (invasive ductal vs. invasive lobular carcinoma; OR: 4.962, 95% CI 1.007–24.441, p = 0.049) and tumor SUVMax value (OR: 0.866, 95% CI 0.755–0.993, p = 0.039) had significant independent efficacy on SM positivity. Initially, 75% underwent SLNB, but nearly half of them needed ALND. ALND rates were significantly higher in the luminal A and LB-HER2(−) groups (87% vs. 69%) than in the HER2(+) and TN groups (43% to 50%) (p = 0.001). All luminal A patients and those with lobular histology required ALND after SLNB, but no patients in the HER2-enriched group required ALND. ER positivity and higher PR expression levels were associated with an increased need for ALND after SLNB, whereas HER2 positivity and higher SUVMax values of LN(s) were associated with a significantly reduced need for ALND. About 27% of the patients achieved overall pCR. No pCR was achieved in the LA group. Conclusions: The BC NACTx process requires close monitoring due to severe AEs and disease progression. NACTx decisions must be made on experienced multidisciplinary tumor boards, considering tumor characteristics and expected targets. [ABSTRACT FROM AUTHOR]
- Published
- 2025
- Full Text
- View/download PDF